Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

Atypical Hemolytic Uremic Syndrome Clinical Trial

— aHUS  

Official title:

An Open-Label, Multi-Center Controlled Clinical Trial Of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic Syndrome (AHUS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00844428
• Other study ID #: C08-003B
• Secondary ID: BB-IND 11075Eudr
• Status: Completed
• Phase: Phase 2
• First received: February 12, 2009
• Last updated: June 30, 2015
• Start date: July 2009
• Est. completion date: December 2013

Study information

• Verified date: June 2015
• Source: Alexion Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health CanadaEuropean Union: European Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 2013
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Male or female patients between ages from 12 and up to 18 years of age weighing = 40 kg who have been diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS).

2. Patients must be receiving PT for aHUS and must be observed to receive = 1 PT treatment every two weeks and no more than 3 PT treatments/week (at an unchanged frequency) for at least 8 weeks before the first dose of IP.

3. Platelet Count Pre-PT Baseline Set-Point (collected in the hours before the Qualifying PT Episode) is within 75% of the average of the pre-PT platelet counts collected at Screening and during the Observation Period.

4. Known complement regulatory protein genetic abnormality.

5. Lactate dehydrogenase (LDH) level at screening or at the onset of the current aHUS episode was = ULN. If LDH is normal at screening, other markers indicative of ongoing hemolysis such as haptoglobin, schistocytes should be evaluated and discussed with Sponsor.

6. Creatinine level = ULN for age.

7. Female patients of childbearing potential must be practicing an effective, reliable and medically approved contraceptive regimen during the entire duration of the study, including the follow-up period and for up to 5 months following eculizumab treatment discontinuation.

8. Patient's parents/legal guardian must be willing and able to give written informed consent and patient must be willing to give written informed assent (if applicable as determined by the IRB/IEC).

9. Able and willing to comply with study procedures.

Exclusion Criteria:

1. TTP, (defined as ADAMTS-13 activity <5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory.

2. Malignancy within 5 years of screening.

3. Typical HUS (Shiga toxin +).

4. Known HIV infection.

5. Identified drug exposure-related HUS.

6. Infection-related HUS.

7. HUS related to bone marrow transplant.

8. HUS related to vitamin B12 deficiency.

9. Patients with a confirmed diagnosis of sepsis.

10. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.

11. Pregnancy or lactation.

12. Unresolved meningococcal disease.

13. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome.

14. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.

15. Patients who have received previous treatment with eculizumab.

16. Patients receiving IVIg within 8 weeks or Rituximab therapy within 12 weeks of the screening visit.

17. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period and throughout the Obeservation Period or [4] patient is experiencing an acute aHUS relapse immediately after transplant.

18. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period or a washout period of at least 2 weeks from the last dose of ESA therapy.

19. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.

20. Hypersensitivity to eculizumab, to murine proteins, or to one of the excipients.

21. Patients between the ages from 12 and up to 18 years weighing < 40 kg.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atypical Hemolytic Uremic Syndrome
• Azotemia
• Hemolysis
• Hemolytic-Uremic Syndrome

Intervention

Drug:
• eculizumab
All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alexion Pharmaceuticals

Countries where clinical trial is conducted

Canada,  France,  Germany,  Italy,  Netherlands,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With TMA Event-free Status	TMA Event-free status is defined as the absence for at least 12 weeks of [1] decrease in platelet count of > 25% from the Platelet Count Pre-PT Baseline Set Point; [2] PT while the patient is receiving eculizumab, and [3] new dialysis.	Through 26 weeks	No
Primary	Percentage of Patients With Hematologic Normalization	Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.	Through 26 weeks	No
Primary	Percentage of Patients With Complete TMA Response	The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as (=25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.	Through 26 weeks	No
Secondary	TMA Intervention Rate	TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.	Through 26 weeks	No
Secondary	Platelet Count Change From Baseline to 26 Weeks		From Baseline to 26 Weeks	No
Secondary	Percentage of Patients With Platelet Count Normalization	Platelet count normalization was defined as the platelet count observed to be =150 x 10^9/L on at least two consecutive measurements which span a period of at least four weeks	Through 26 Weeks	No
Secondary	Percentage of Patients With TMA Event-free Status	TMA Event-free status is defined as the absence for at least 12 weeks of [1] decrease in platelet count of > 25% from the Platelet Count Pre-PT Baseline Set Point; [2] PT while the patient is receiving eculizumab, and [3] new dialysis.	Through End of Study, Median Exposure 156 Weeks	No
Secondary	Percentage of Patients With Hematologic Normalization	Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.	Through End of Study, Median Exposure 156 Weeks	No
Secondary	Percentage of Patients With Complete TMA Response	The proportion of patients who achieved a Complete TMA Response from baseline through end of study with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as (=25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.	Through End of Study, Median Exposure 156 Weeks	No
Secondary	TMA Intervention Rate	TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of study) for PE/PI and (from the fifteenth day following the first eculizumab dose through end of study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.	Through End of Study, Median Exposure 156 Weeks	No
Secondary	Platelet Count Change From Baseline to 156 Weeks		From Baseline to 156 Weeks	No
Secondary	Percentage of Patients With Platelet Count Normalization	Platelet count normalization was defined as the platelet count observed to be =150 x 10^9/L on at least two consecutive measurements which span a period of at least four weeks Not specified.	Through End of Study, Median Exposure 156 Weeks	No
Secondary	Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration		Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer.	No